Wu et al. reported that CREKA peptide loaded contrast agent CREKA-dl-(DOTA-Gd)4 provided MRI contrast enhancement of PCa xenografts in mice by targeting fibronectin [19]. Here, FN1 is linked to posterior cortical atrophy.